Archive | July, 2020

Pitch Perfect

16 Jul

By Rory McCann, Marketing Manager & Conference Producer, LSN

Pitching your company to investors may be one of the most daunting duties of an early-stage CEO, but a confident, concise, and compelling pitch may be what stands between you and your fundraising goals. Life Science Nation (LSN) CEO, Dennis Ford lays out a roadmap navigating investor pitches and more on The Life Science Executive’s Fundraising Manifesto, and includes tips to nail a pitch session:

Tell your story. When investors have a foundational understanding of the roots of your organization, they get a better feel for the drivers of the company as a whole and can more easily put their trust in you.

Address the market. Discuss the medical need your product is addressing and what treatment options are currently available for it. Here you have the opportunity to capture the investors’ attention by showing them the potential revenue their firm may realize if your product reaches the market.

Hit them with the technology. Having high energy and excitement when explaining the technology shows that you yourself believe in the product and that what you are working on is innovative and investment-worthy.

Know what you want. Highlight exactly how much of the requested funding is going to be spent on the various activities your company must perform.

Remember that practice makes perfect. A CEO needs to be comfortable delivering the pitch at any point in time. Be prepared to introduce your company clearly and concisely, and make sure to practice delivering the important details, whether you have one minute or five.

LSN is introducing two new opportunities for life science executives to get their message in front of investors. Digital RESI September and 4D Meets AI are two partnering conferences where early-stage companies can apply for a spot on a Featured Company Pitch Session. These sessions enable CEOs to pitch directly investors and host a live Q&A session. Each company delivers a pre-recorded pitch hosted on a dedicated page enabled for downloadable materials and connected to a live agenda for easy access and optimal exposure.

Featured Company Pitch Sessions ensures that companies are seen and that their messages are heard. Click here to apply for a spot at Digital RESI September, which connects early-stage products with capital and channel partners. Click here to apply for a spot at 4D Meets AI, advancing drugs, devices, diagnostics, and digital health through the power of artificial intelligence.

Panel Spotlight: AI Diagnostics for Disease Detection

16 Jul

By Bryanna Allison, Business Development Manager, LSN

This September, Life Science Nation (LSN) is launching the Inaugural 4D Meets AI partnering conference, providing a platform for all companies developing and commercializing Drugs, Devices, Diagnostics, and Digital Health (the 4 Ds), with an Artificial Intelligence (AI) vertical, to meet and connect with investors and strategic partners. In addition to partnering meetings and presentation opportunities, 4D Meets AI will welcome a complete agenda of investor and application panels to expand industry knowledge in the latest trends and developments.

One of the application panels, AI Diagnostics for Disease Detection, features some of the brightest minds shaking up the standard with revolutionary tech and applications. Deep learning diagnostics holds immense potential to enhance both the speed and accuracy of disease diagnoses. The diagnostic information that AI absorbs comes from various silos, including symptom data, disease causes, test results, medical images, doctor reports and more. AI can accurately identify disease diagnoses in these data sets and has become a viable source of diagnostic information. AI and machine learning can improve diagnostic accuracy, cut costs, and improve patient safety worldwide. The following industry experts will participate in a dynamic discussion about the current landscape and where the industry is headed.

Marty Keiser, Founder & CEO, IV BioHoldings, LLC (Moderator)

Bio development studio, IV BioHoldings (IVBH) is a bio innovation studio that creates disease-specific startups at the intersection of bioinformatics, biology, and business. The IVBH studio taps a vast internal network in search of big addressable markets with major unmet medical needs, where there is an opportunity to generate economic value for patients, payers, and stakeholders. Each venture creation is defined by its virtual business model, data and technology-heavy R&D process, and a core focus on transcriptomics; illuminating biological insights required for the comprehensive detection, diagnosis, and treatment of a particular disease. To date, IVBH has accelerated breakthrough innovations in lung cancer and liver disease (NASH) and is currently incubating projects across a number of indications that affect similarly large populations. By connecting data, technology, and capital, the studio hopes to break down the traditional barriers that exist between diagnostics and therapeutics and accelerate access to effective and affordable solutions across the entire care continuum.

Meesha Dogan, PhD, Co-Founder & CEO, Cardio Diagnostics, Inc.

Cardio Diagnostics, Inc. is a precision medtech company transforming the prevention of cardiovascular disease. They will soon be launching Epi+Gen CHD, the first at-home, end-to-end remote, clinical AI-driven DNA test that profiles and aggregates genetic and epigenetics biomarkers for heart attack risk screening. The underlying technology is also being incorporated into a series of products for stroke, heart failure and other comorbidities. Their vision is to transform the medical care for cardiovascular disease (CVD) from reactive to proactive. They believe that prevention and early detection should be the norm, and that epigenetics-based technologies driven by AI will unlock the new era of highly accessible Precision Cardiovascular Medicine. They are leading this change through their own technologies and in conjunction with key stakeholders and strategic partners to enable better health outcomes.

Nan-Wei Gong, PhD, Founder & CEO, FIGUR8, Inc.

Founded in 2016, FIGUR8 is a MIT STEX 25 company formed by a group of engineers, researchers and designers with expertise in wearable computing, digital health and sports science. They share the same passion in creating the most intuitive and effective way to understanding human movement and to bring what’s only available to the elite few today to the hands of the everyday user.

 

Marc Lambrechts, PhD, Senior Investment Manager, Capricorn Partners NV

Capricorn Partners NV is an independent manager of private and quoted equity funds that invest in minority shareholding positions of innovative companies with technology as competitive advantage. Capricorn Venture Partners NV was established in early 1993 as a joint venture between Dr. Jos B. Peeters and Baring Venture Partners Ltd, In December 1999, Professor Philippe Haspeslagh, the chairman of Capricorn Venture Partners and Jos acquired the shares held by Barings (then ING) and the company has since been operating as a fully partner-owned independent management company. In line with its growths into a specialized alternative asset manager, the company was renamed in Capricorn Partners in August 2019. Their mission is to create financial return for clients and support spearheading entrepreneurs that have developed products with a true impact.

Andrea Wang, MS, Co-Founder & CEO, AHEAD Medicine

AHEAD Medicine focuses on developing AI-powered diagnostics for blood cancer precision medicine. They’ve developed AHEAD-flow, the fully automated immunophenotype analysis platform which allows physicians to identify abnormal cases promptly and avoid delays in clinical decisions. Their vision: To enable AI aided clinical decision making in cancer treatment for every physician and to identify, with greater ease, optimization paths to better treatment strategies.

Visit our agenda to view additional panels.

4D Meets AI is still accepting panelist applications. AI Investors Click Here and AI CEOs Click Here to fill out an application for consideration. 

The Digital Sponsorship Model Works, Providing Bang for Sponsor Dollars

16 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The world of partnering and life science conferences has moved from the function hall to the world wide web. Exhibit halls once ringing with chatter and the sound of house wine-filled glasses are now silent, giving way to server buzzing and unintentional background noise when you’re certain your Zoom account was already muted… The question remains: how can companies leverage digital event sponsorship, and is the virtual exposure worth the very real, non-virtual cost?

The answer is yes – companies that would normally be interested in sponsoring partnering and life science conferences, should be throwing their hats into the virtual arena. Digital platforms are providing more flexibility and evening the playing field. Sponsors no longer need to pray for a prime booth near the food and beverage corner or impress potential partners with better branded t-shirts and water bottles. There is direct-to-consumer access that aligns with the values of partnering events – connecting the buyers and the sellers to move the needle in early-stage life science partnering.

Service Providers Can Leverage Digital Events

Life Science Nation (LSN)’s ecosystem has always been deal-focused and transaction-centric from its inception. LSN partnering conferences are experiential, interactive, and frequent, to promote continuing development of business relationships, all the way up to the closing of contracts. While the onsite model has changed to a web-based platform, the mission remains the same, with increased access and flexibility.

Virtually any service provider who has a product to sell to early-stage CEOs can really be successful getting their message out at online partnering events. Half the attendees at LSN partnering events are raising capital to spend on the services they need to develop their products, and our sponsors are able to not only find the right companies that are a fit for their own products and services, but also have the extra added capability of learning about the bevy of portfolio companies that are sitting in LSN’s vast investor network.

CROs, CMOs, legal, staffing, consulting, accounting – all the service providers that make the healthcare ecosystem thrive have successfully used LSN partnering events to deliver their message and develop their brand. The good news is that the latest move by LSN to feature elongated digital partnering events has increased attendance by 30% and opened-up the global market to our sponsors.

LSN Partnering Events See Attendance Surge, Boding Well for Sponsors

Being a sponsor at LSN partnering events is a great way for companies in the early-stage life science arena to increase their brand and garner global attention. LSN has 2,000+ fundraising CEOs regularly attending Redefining Early Stage Investments (RESI) events, and the same growth trend applies to LSN’s investors, channel partners and the Pharma network. Funded early-stage life science CEOs are still meeting at the proverbial water hole, and its web-based features enable sponsors to actively engage with their target audience and close the deals that save lives.

Check Out LSN’s Digital Partnering Conference Sponsorship Brochures Below:

Hot Investor Mandate: Newly Founded Venture Arm of Global Advisory Firm Invests in Early-Stage Devices, Diagnostics, Digital Health Companies

16 Jul

A venture arm of a global advisory dedicated to healthcare with practices across regulatory and clinical affairs, market access and HEOR strategy consulting, and investment banking uses its experience in the industry to invest in promising early stage companies developing medical devices, diagnostics or digital health technologies. The firm invests at the seed stage, and serves as a strategic investor as much as a financial investor, using industry knowledge and contacts to help companies grow. The firm will generally invest between $250K-1M in companies that have some proof of concept and IP. The firm will invest globally.

The firm invests in medical device, diagnostics and digital health companies. While the firm is generally agnostic to subsector and indication, it tends to avoid companies with a long time to exit. In addition, while the firm is willing to consider all types of medical devices, they are less likely to invest in PMA devices at this stage.

The firm is a very active investor, and thus takes a board seat, even if just an observer position, to lend their expertise. The firm can lead or coinvest, but tends to coinvest, and can help build a syndicate with their contacts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Corporation Seeks Strategic Investment & Partnership Opportunities in Early-Stage Therapeutics in Cardiovascular Disease, Oncology, and More

16 Jul

Headquartered in China, a publicly traded corporation (SHA:600535) is dedicated to building a top-tier, modern, and international brand in pharmaceutical products. The firm provides modernized traditional Chinese medicines (TCMs), small molecule and biological drugs. The firm is actively pursuing strategic partnerships with pharmaceutical companies and bio-techs from domestic and overseas in the abovementioned therapeutic areas. The firm considers a board range of strategies including strategic investment, joint venture, acquisition, licensing, and co-development.

The firm is looking for strategic partnerships in chemical drugs and biological drugs. The firm is open to products at clinical to launched stages in therapeutic areas of cardiovascular, cerebrovascular diseases, oncology, diabetes, liver disease and so on.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Life Sciences Investment Fund Partnered with a Family Office Invests in Seed Stage Therapeutics, Devices, Diagnostics, Life Science Tools Technologies in USA

16 Jul

A life sciences investment fund dedicated to accelerating the growth of seed-stage therapeutics companies. In partnership with a family investment office, the firm seeks to make 2-3 new investments by the end of 2020, allocating up to $250,000 per company. The firm invests in companies based in the U.S.

The firm is seeking investments in therapeutics, medical devices, diagnostics and life science tools. For therapeutics companies, the firm prefers treatments for diseases with well-defined etiologies, as well as clear method of action that are in late pre-clinical stage. For diagnostics, device and life science tools, the firm invests in companies that are approaching clearance and/or market launch.

The firm does not have any specific company or management team requirements. The firm is a strategic as well as financial investor, helping companies develop relationships and accelerate growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan-Based Investment Firm Invests Globally into Therapeutics Platforms, Devices, and Services

16 Jul

A biotech early stage investment firm headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →